Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | BMP1 | P13497 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27821451 | 0.84 | CYP1A2 (0.64) | CYP1A2CYP2C9CYP2C19MAPTKMT2A | |
| SCHEMBL15380249 | 0.80 | CYP1A2 (0.77) | CYP1A2CYP2C9CYP2C19MAPTKMT2A | |
| SCHEMBL4842646 | 0.79 | CYP1A2 (0.71) | CYP1A2CYP2C9CYP2C19MAPTKMT2A | |
| SCHEMBL3514061 | 0.79 | LMNA (0.56) | CYP1A2CYP2C9CYP2C19MAPTKMT2A | |
| SCHEMBL12585035 | 0.79 | MEN1 (0.76) | CYP1A2CYP2C9CYP2C19MAPTKMT2A | |
| SCHEMBL28983376 | 0.78 | CYP1A2 (0.74) | CYP1A2CYP2C9CYP2C19MAPTKMT2A | |
| SCHEMBL22315220 | 0.76 | CYP1A2 (0.71) | CYP1A2CYP2C9CYP2C19MAPTKMT2A | |
| SCHEMBL4008435 | 0.76 | CYP1A2 (0.70) | CYP1A2CYP2C9CYP2C19MAPTKMT2A | |
| SCHEMBL3771813 | 0.75 | PTGES2 (1.00) | CYP1A2CYP2C9CYP2C19MAPTKMT2A | |
| SCHEMBL4836493 | 0.75 | KDM4E (0.52) | CYP1A2CYP2C9CYP2C19MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| EP-2234993-B1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2012-11-07 | — | — | EP | disclosed |
| CN-101945859-A | Bis-(sulfonylamino) derivatives in therapy | ASTRAZENECA AB | 2011-01-12 | — | — | CN | disclosed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | PTGER1, SULT2A1, SULT1E1 | CYP1A2 21/4885CYP2C9 47/4885CYP2C19 53/4885 |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | PTGER1, SULT2A1, SULT1E1 | CYP1A2 16/4885CYP2C9 29/4885CYP2C19 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.